Psychotic Disorders - Japan | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$324.30m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of -0.56%, resulting in a market volume of US$315.40m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$254.40 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Japan is experiencing significant growth due to several factors.

Customer preferences: In Japan, there is a growing demand for effective treatments and support for individuals with psychotic disorders. Customers are increasingly seeking out medications and therapies that can help manage symptoms and improve quality of life. Additionally, there is a preference for treatments that have minimal side effects and are well-tolerated.

Trends in the market: One of the key trends in the Psychotic Disorders market in Japan is the increasing use of atypical antipsychotic medications. These medications have been shown to be effective in managing symptoms of psychotic disorders while also having a lower risk of side effects compared to older, typical antipsychotics. This trend is driven by the desire for improved treatment outcomes and better tolerability among patients.Another trend in the market is the growing adoption of psychosocial interventions alongside medication. Psychosocial interventions, such as cognitive-behavioral therapy and family therapy, have been shown to be effective in reducing symptoms and improving functioning in individuals with psychotic disorders. This trend reflects a shift towards a more holistic approach to treatment that addresses not only the biological aspects of the disorder but also the psychological and social factors that contribute to its development and maintenance.

Local special circumstances: Japan has a unique healthcare system that heavily emphasizes universal coverage and accessibility. This means that individuals with psychotic disorders have relatively easy access to healthcare services, including medications and therapies. The government also plays a significant role in regulating and subsidizing the cost of medications, making them more affordable for patients. These special circumstances contribute to the growth of the Psychotic Disorders market in Japan by ensuring that individuals have access to the necessary treatments and support.

Underlying macroeconomic factors: Japan has a rapidly aging population, with a significant proportion of the population being over the age of 65. Psychotic disorders, such as schizophrenia, often have an onset in early adulthood and can have a chronic course. As the population ages, the prevalence of psychotic disorders is expected to increase, driving demand for treatments and support services. Additionally, Japan has a high level of healthcare spending, which further supports the growth of the Psychotic Disorders market.In conclusion, the Psychotic Disorders market in Japan is experiencing growth due to customer preferences for effective treatments and support, the increasing use of atypical antipsychotic medications, the adoption of psychosocial interventions, the unique healthcare system in Japan, and underlying macroeconomic factors such as an aging population and high healthcare spending.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.